Hybrid ocular delivery system of cyclosporine-A comprising nanomicelle-laden polymeric inserts with improved efficacy and tolerability.

We report on hybrid nanomicelle-polymer insert for improved delivery of cyclosporine A (CyA) to the surface of the eye. Hybrid inserts containing the nanomicellar formulation were prepared by the solvent...

OCULAR DRUG DELIVERY SYSTEM: CHALLENGES AND APPROACHES

The ocular drug delivery deviates through a number of anatomical and physiological barriers, which have been a bottleneck for the ophthalmologists. The ocular barriers, static and dynamic, decrease the absorption of the therapeutic agents and the entry of the xenobiotics. Thus, a conventional ocular dosage form has various disadvantages of its use in ocular diseases. Hence, an ideal ocular delivery system has always been aimed, where the bioavailability of a drug is maintained for a longer period of time. The present review aims to focus on the drawbacks of the conventional ocular therapy and the advantages of designing novel delivery systems, with their certain specific advantages in ocular pharmacokinetics and the enhancement of bioavailability. These novel approaches emphasize on the benefits of various ocular drug delivery systems, like eye ointments, gels and use of viscosity enhancers, prodrugs, penetration enhancers, microparticles, liposomes, niosomes, ocular inserts, implants, intravitreal injections, nanoparticles, nanosuspension, microemulsion, dendrimers, in situ gels, iontophoresis and periocular injections. The compiled data presented in this review will act as a good information resource and reference point for further researches in the field of ocular drug delivery aiming non-invasive sustained release of drugs in the anterior and posterior segments of the eye.

Development of Moxifloxacin Hydrochloride Thermoreversible Ocular Delivery System for the Treatment of Conjunctivitis

The present investigation deals with formulation and development of novel ophthalmic in situ gel formulation of Moxifloxacin in order to treat common disorder of conjunctivitis. The formulation contains combination of two polymers like Poloxamer 4–7 and chitosan both help in sustaining and increasing the drug release as well as retention time of drug at contact site. Thus developed formulation was evaluated for various parameters. The moxifloxacin in situ gel was found to be clear with ph in range of 6.8–7.0. The gelling time was also found to be quick with prolong retention up to 8 hrs. The optimized batch showed maximum release of 99.98% and was found to have sustained action when compared to marketed ophthalmic eye drop formulation. The formulation of Ophthalmic Thermosensitive in situ gel for Moxifloxacin was successfully prepared using Polymer combination of Poloxamer 407 and chitosan and found effective in the treatment of Conjunctivitis.